111 related articles for article (PubMed ID: 12050546)
1. Lymphangioma of the renal capsule.
Zapzalka DM; Krishnamurti L; Manivel JC; DiSandro MJ
J Urol; 2002 Jul; 168(1):220. PubMed ID: 12050546
[No Abstract] [Full Text] [Related]
2. The challenge of kidney lesions in von Hippel-Lindau disease.
Neumann HP; Riegler P; Huber W; Corradini R; Sessa A; Fontana D; Wetterauer U; Janetschek G
Contrib Nephrol; 2001; (136):193-207. PubMed ID: 11688380
[No Abstract] [Full Text] [Related]
3. [Current progress in the diagnosis and treatment of renal cell carcinoma].
Tsukamoto T; Takahashi A; Kitamura H
Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):779-85. PubMed ID: 12607966
[No Abstract] [Full Text] [Related]
4. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
[TBL] [Abstract][Full Text] [Related]
5. [Cystic lymphangioma of the kidney. Clinical and morphologic findings].
Bettendorf U; Köllner D; Köllermann M; Kiefer H
Urologe A; 1985 Jan; 24(1):52-5. PubMed ID: 3885545
[TBL] [Abstract][Full Text] [Related]
6. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
Richard S
Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
[No Abstract] [Full Text] [Related]
7. Editorial: Kidney cancer--a unique opportunity for the development of disease specific therapy.
Linehan WM
J Urol; 2002 Dec; 168(6):2411-2. PubMed ID: 12441928
[No Abstract] [Full Text] [Related]
8. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
11. VHL and kidney cancer.
Ohh M; Kaelin WG
Methods Mol Biol; 2003; 222():167-83. PubMed ID: 12710686
[No Abstract] [Full Text] [Related]
12. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting of VHL gene pathway in clear cell kidney cancer.
Linehan WM
J Urol; 2003 Aug; 170(2 Pt 1):593-4. PubMed ID: 12853837
[No Abstract] [Full Text] [Related]
14. Risk factors, genetic predisposition and mutations in the VHL gene in sporadic renal cell carcinoma: The Netherlands Cohort Study.
Van Dijk BA; Schouten LJ; Hulsbergen-van de Kaa CA; van Houwelingen KP; Schalken JA; Kiemeney LA; Geurts van Kessel AH; Bausch-Goldbohm RA; van den Brandt PA
IARC Sci Publ; 2002; 156():509-10. PubMed ID: 12484247
[No Abstract] [Full Text] [Related]
15. Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma.
Barnabas N; Amin MB; Pindolia K; Nanavati R; Amin MB; Worsham MJ
J Surg Oncol; 2002 May; 80(1):52-60. PubMed ID: 11967908
[TBL] [Abstract][Full Text] [Related]
16. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
17. [Frequent somatic mutations of the von Hippel-Lindau tumor suppressor gene in primary sporadic human renal clear cell carcinomas].
Gong K; Zhang Z; Xin D
Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(3):142-4. PubMed ID: 11798864
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioma of the kidney.
Honma I; Takagi Y; Shigyo M; Sunaoshi K; Wakabayashi J; Harada O; Miyao N
Int J Urol; 2002 Mar; 9(3):178-82. PubMed ID: 12010331
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
[TBL] [Abstract][Full Text] [Related]
20. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
